LATEST PRESS RELEASE
Amorfix appoints Mr. Johannes Roth to Board of Directors
December 5, 2013
Amorfix to provide ALS blood test diagnostic update at the MND/ALS 24th International Symposium
December 2, 2013
Amorfix announces fiscal 2014 second quarter results
November 13, 2013
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's Disease.
Amorfix is a pioneer in the ability to identify unique regions that are buried in normal proteins, and exposed to antibodies when proteins are aberrantly folded. These unique regions are designated Disease Specific Epitopes™ (DSE), which can be exploited by Amorfix to develop highly specific diagnostic tools, as well as targets for therapeutics of protein misfolding diseases.